Minerva Neurosciences, Inc. (NASDAQ:NERV) Files An 8-K Other EventsItem 8.01
On March 16, 2017 and March 17, 2017, certain investors in Minerva Neurosciences, Inc.’s (the “Company”) previously announced March 2015 private placement exercised their warrants. Upon exercise, the Company issued the investors an aggregate of 1,418,439 shares of the Company’s common stock. The Company received gross proceeds of $8,187,229.91 from the exercise prices of the exercised warrants.
About Minerva Neurosciences, Inc. (NASDAQ:NERV)
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system (CNS) diseases. The Company’s product portfolio include MIN-101 for the treatment of schizophrenia; MIN-117 for the treatment of major depressive disorder (MDD); MIN-202 (also known as JNJ-42847922) for the treatment of insomnia disorder and adjunctive MDD, and MIN-301 for the treatment of Parkinson’s disease. MIN-101 blocks serotonin receptors and sigma receptors, over two receptors in the brain that are involved in the regulation of mood, cognition, sleep and anxiety. MIN-117 is meant to block a specific subtype of serotonin receptor called 5-HT1A. MIN-202 is a selective orexin 2 receptor antagonist it is developing in collaboration with Janssen Pharmaceutica NV. MIN-301 is a soluble recombinant form of the Neuregulin-1b1 protein. Minerva Neurosciences, Inc. (NASDAQ:NERV) Recent Trading Information
Minerva Neurosciences, Inc. (NASDAQ:NERV) closed its last trading session down -0.40 at 7.75 with 249,023 shares trading hands.